MaxCyte Investor Presentation Deck

EXPERT™ Platform Addresses Industry Challenges Challenges A⁰ C Lack of industry standard for process design causes development to be costly and inconsistent across manufacturing runs Next-generation cell therapy programs have become increasingly complex requiring multiple edits Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) Vein-to-vein manufacturing times are high; optimizations needed to deliver medicines to patients faster MaxCyte's Solutions A (✓: 8 M MaxCyte MaxCyte technology allows plug and play processes with rapid optimization delivering reproducible outcomes and the ability to seamlessly scale up from pre-IND to the clinic and commercialization Flow Electroporation® technology facilitates multiplex and sequential engineering without the payload and capacity limitations of viral approaches FDA Master File can be referenced in regulatory filings to accelerate and de-risk regulatory review EXPERT™ platform provides industry leading transfection efficiency & cell viability at high scale in 30 minutes or less, enabling manufacturers to quickly scale up production © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation